[1] Goubraim R, Kabbaj N, Salihoun M, et al. Metabolic bone disease in viral cirrhosis: A prospective study. ISRN Hepatol, 2013, 2013: 1-6.
[2] Gonzalez-Calvin JL, Gallego-Rojo F, Fernandez-Perez R, et al. Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis. J Clin Endocrinol Metab, 2004, 89: 4325-4330.
[3] Wijarnpreecha K, Thongprayoon C, Panjawatanan P, et al. Hepatitis C virus infection and risk of osteoporosis: A meta-analysis. Saudi J Gastroenterol, 2017, 23: 216-221.
[4] Arase Y, Suzuki F, Suzuki Y, et al. Prolonged-efficacy of bisphosphonate in postmenopausal women with osteoporosis and chronic liver disease. J Med Virol, 2008,80: 1302-1307.
[5] González-Calvin JL, Mundi JL, Casado-Caballero FJ , et al. Bone mineral density and serum levels of soluble tumor necrosis factors, estradiol, and osteoprotegerin in postmenopausal women with cirrhosis after viral hepatitis. J Clin Endocrinol Metab, 2009, 94: 4844-4850.
[6] Hofmann WP, Kronenberger B, Bojunga J, et al, Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon alpha and ribavirin therapy. J Viral Hepat, 2008, 15: 790-796.
[7] Redondo-Cerezo E, Casado-Caballero F, Martin-Rodriguez JL, et al. Bone mineral density and bone turnover in non-cirrhotic patients with chronic hepatitis C and sustained virological response to antiviral therapy with peginterferon-alfa and ribavirin. Osteoporos Int, 2014, 25: 1709-1715.
[8] Barbu EC, Chitu-Titu CE, Lazar M, et al. Body composition changes in patients with chronic hepatitis C. J Gastrointestin Liver Dis, 2016, 25: 323-329.
[9] 苏森,赵彩彦,赵欣.等.慢性乙型病毒性肝炎患者在阿德福韦酯治疗期间血磷浓度和骨密度的变化.中华内科杂志,2015,54:332-333.
[10] 邱贵兴,裴福兴,胡侦明.等.中国骨质疏松性骨折诊疗指南(全文)(骨质疏松性骨折诊断及治疗原则.中华关节外科杂志,2015,9:795-798.
[11] Eltayeb AA, Abdou MA, Abdel-aal AM, et al. Vitamin D status and viral response to therapy in hepatitis C infected children. World J Gastroenterol, 2015, 21: 1284-1291.
[12] Compston J, Cooper A, Cooper C, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos, 2017, 12: 43.
[13] Zhao JG, Zeng XT, Wang J, et al. Association Between Calcium or Vitamin D Supplementation and Fracture Incidence in Community-Dwelling Older Adults: A Systematic Review and Meta-analysis. JAMA, 2017, 318: 2466-2482.
[14] Yurci A, Kalkan AO, Ozbakir O, et al. Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease. Eur J Gastroenterol Hepatol, 2011, 23:1206-1212.
[15] 刘欣瑜,陈军. 警惕抗骨质疏松药物伊班膦酸盐导致的严重肝损伤. 肝脏,2014, 19:215-217.
[16] Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3-year randomized clinical trial Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA, 1999 ,282:637-645.
[17] Takeda M, Ikeda M, Mori K, et al. Raloxifene inhibits hepatitis C virus infection and replication. FEBS Open Bio, 2012, 2: 279-283.
[18] Furusyo N, Ogawa E, Sudoh M, et al. Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial. J Hepatol, 2012, 57: 1186-1192.
[19] 中华医学会骨科学分会,骨质疏松骨折诊疗指南.中华骨科杂志. 2008, 28: 875-878.
[20] Valero MA, Loinaz C, Larrodera L, et al. Calcitonin and bisphosphonates treatment in bone loss after livertransplantation. Calcif Tissue Int, 1995, 57: 15-19.
[21] Shiomi S, Masaki K, Habu D, et al. Calcitrol for bone disease in patients with cirrhosis of the liver Calcitriol for cirrhosis-associated bone disease. J Gastroenterol Hepatol, 1999, 14: 547-552.
[22] Shiomi S, Nishiguchi S, Kubo S, et al. Vitamin K2 (menatetrenone) for bone loss in patients with cirrhosis of the liver. Am J Gastroenterol, 2002, 97: 978-981.
[23] Handzlik-Orlik G, Holecki M, Wilczyński K, et al. Osteoporosis in liver disease pathogenesis and management. Ther Adv Endocrinol Metab, 2016, 7: 128-135. |
